Dr. John Baust (CPSI President) commented, “The overall objective of FrostBite is to provide a powerful ablative tool to attack pancreatic cancer, which ultimately may reduce our reliance on other more traditional approaches such as chemotherapy, radiation or major surgery to treat this deadly disease.” The potential impact of the technology is tremendous. Speaking about the technology, Dr. P. Jay Pasricha (Professor of Medicine and Neurosciences, Division of Gastroenterology, John Hopkins School of Medicine and consultant for CPSI) commented “We are very encouraged by the potential of FrostBite EUS-cryocatheter platform. The ability to target and freeze tissues in situ under endoscopic ultrasound guidance will provide for a more precise and minimally invasive strategy to treat cancer including pancreatic, esophageal and other tumors. We are looking forward to continuing our work with CPSI to bring this technology to the clinic.” Read more . . .